Kevin DeGeeter

Novavax, Inc. (NASDAQ: NVAX) announced Monday after the close an award of an incremental $384 million in funding by the Coalition for Epidemic Preparedness Innovations alongside forecast-beating first-quarter results. The Novavax Analysts H.C. Wainwright analyst Vernon Bernardino reiterated a Buy...

Analysts at Ladenburg Thalmann turned incrementally bullish on Ignyta Inc (NASDAQ: RXDX) after the company's therapy for the treatment of rare lung cancer showed encouraging results in a preliminary clinical trial among patients with a defective cancer-causing gene that is found in around 2...

Versartis Inc (NASDAQ: VSAR) shares are slumping even as rival Opko Health Inc. (NASDAQ: OPK) is seeing slight strength, though not proportionate to the sell-off seen in Versartis shares. News Behind The Move Versartis announced Thursday after the market close that its Somavaratan, a long-...

If you've been too distracted by the Snap Inc (NYSE: SNAP) IPO lottery ticket trade to keep your eye on small-cap biotech moves, you may not have noticed VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV) shares quietly doubling in value since the start of the year. VBI Vaccines is a...

“While we continue to believe Novavax, Inc. (NASDAQ: NVAX) has an active vaccine for the prevention of RSV (Respiratory syncytial virus), we view a Neutral rating as appropriate given limited visibility on optimal dose/schedule for future development in an elderly population and modest...

Ladenburg Thalmann upgraded shares of Myriad Genetics, Inc. (NASDAQ: MYGN), premised on valuation, as it views that the sell thesis has largely played out. Q2 Largely In Line Analyst Kevin DeGeeter noted that the company reported second-quarter non-GAAP earnings of $0.26 per share on revenues...

Shares of Opko Health Inc. (NASDAQ: OPK) slumped after the release of mixed results from a Phase III clinical study of long-acting human growth hormone [hGH-CTP] candidate in adults with growth hormone deficiency. “We view the sell off as overblown and an opportunity to acquire shares,...

Ladenburg Thalmann has downgraded Cempra Inc (NASDAQ: CEMP) to Neutral from Buy following the complete response letter from the FDA for Solithromycin for treatment of Community Acquired Bacterial Pneumonia (CABP). The letter cites both manufacturing deficiencies at contract manufacturer Wockhardt...

Top-line Phase III data for Novavax, Inc’s (NASDAQ: NVAX) RSV F nanoparticle vaccine for the prevention of RSV in the elderly was disappointing, Ladenburg’s Kevin DeGeeter said in a report. He downgraded the rating on the company from Buy to Neutral, and removed the price target....

Shares of Sequenom, Inc. (NASDAQ: SQNM) are down roughly 13 percent on Tuesday trading, following the company's investor day event on Monday. Following the gathering, analysts at Ladenburg Thalmann downgraded shares of the company from Neutral to Sell, setting a $0.90 price target. According to a...

The following represents a hand-picked selection of notable research curated by an analyst known in some circles as "The Sith Overlord Of The Street." JPMorgan: Downgrading Linn Energy Gabriel Daoud of JPMorgan downgraded shares of both Linn Energy LLC (NASDAQ: LINE) and LinnCo LLC (NASDAQ:...